Arcutis Biotherapeutics
ARQT
ARQT
185 hedge funds and large institutions have $1.18B invested in Arcutis Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 59 increasing their positions, 55 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
0.57% more ownership
Funds ownership: 108.71% → 109.28% (+0.57%)
5% less capital invested
Capital invested by funds: $1.24B → $1.18B (-$61.9M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Holders
185
Holding in Top 10
4
Calls
$7.03M
Puts
$2.73M
Top Buyers
| 1 | +$21.5M | |
| 2 | +$19.8M | |
| 3 | +$18.3M | |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$12.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.47M |
Top Sellers
| 1 | -$33.9M | |
| 2 | -$16.3M | |
| 3 | -$12.9M | |
| 4 |
SC
Stempoint Capital
New York
|
-$11.5M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$9.12M |